Targeted Immunotherapies for Cancers

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jan 11

PMID 38201439

Authors

Anthony Cheung

Alicia Chenoweth

Affiliations

Soon will be listed here.

Abstract

Advancements in immunotherapy have revolutionized cancer treatment in a broad variety of hematological and solid malignancies and rejuvenated the field of cancer immunology [...].

References

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

Gansauge S, Gansauge F, Beger H . Molecular oncology in pancreatic cancer. J Mol Med (Berl). 1996; 74(6):313-20. DOI: 10.1007/BF00207508. View

Mazor R, King E, Pastan I . Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins. Am J Pathol. 2018; 188(8):1736-1743. PMC: 6099333. DOI: 10.1016/j.ajpath.2018.04.016. View

Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert J . Antibodies to watch in 2023. MAbs. 2022; 15(1):2153410. PMC: 9728470. DOI: 10.1080/19420862.2022.2153410. View

Adams S, Schmid P, Rugo H, Winer E, Loirat D, Awada A . Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2018; 30(3):397-404. DOI: 10.1093/annonc/mdy517. View

Dirix L, Takacs I, Jerusalem G, Nikolinakos P, Arkenau H, Forero-Torres A . Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2017; 167(3):671-686. PMC: 5807460. DOI: 10.1007/s10549-017-4537-5. View

Sauna Z, Lagasse D, Pedras-Vasconcelos J, Golding B, Rosenberg A . Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins. Trends Biotechnol. 2018; 36(10):1068-1084. DOI: 10.1016/j.tibtech.2018.05.008. View

Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G . Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022; 15(1):163. PMC: 9636687. DOI: 10.1186/s13045-022-01376-3. View

Cheung A, Chenoweth A, Quist J, Sow H, Malaktou C, Ferro R . CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. Cancers (Basel). 2022; 14(14). PMC: 9322647. DOI: 10.3390/cancers14143361. View

10.

Pitt J, Vetizou M, Daillere R, Roberti M, Yamazaki T, Routy B . Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity. 2016; 44(6):1255-69. DOI: 10.1016/j.immuni.2016.06.001. View

11.

Munoz-Lopez P, Ribas-Aparicio R, Becerra-Baez E, Fraga-Perez K, Flores-Martinez L, Mateos-Chavez A . Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy. Cancers (Basel). 2022; 14(17). PMC: 9455005. DOI: 10.3390/cancers14174206. View

12.

Merrick K, Wohlbold L, Zhang C, Allen J, Horiuchi D, Huskey N . Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Mol Cell. 2011; 42(5):624-36. PMC: 3119039. DOI: 10.1016/j.molcel.2011.03.031. View

13.

ODonnell J, Teng M, Smyth M . Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2018; 16(3):151-167. DOI: 10.1038/s41571-018-0142-8. View

14.

Albinger N, Pfeifer R, Nitsche M, Mertlitz S, Campe J, Stein K . Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 2022; 12(4):61. PMC: 9007937. DOI: 10.1038/s41408-022-00660-2. View